Chemotherapy Clinical Trial
Official title:
To Observe a Single-center, Randomized, Controlled Clinical Study on the Effect of Douyin on the Emotions of Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy
Verified date | November 2023 |
Source | Henan Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A total of 90 patients with bone and soft tissue malignancies who planned to receive chemotherapy were enrolled in this study in Henan Cancer Hospital. They were divided into experimental group and control group for anxiety and depression value 24 hours before chemotherapy, anxiety and depression value on the day of chemotherapy, anxiety value and depression value 24 hours after chemotherapy. To evaluate the effects of watching Tik Tok on perichemotherapy anxiety and depression in patients with bone and soft tissue malignant tumors who were to receive chemotherapy, and to evaluate the effects of watching Tik Tok on the incidence of chemotherapy-related complications in patients with bone and soft tissue malignant tumors who were to receive chemotherapy.
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 70 Years |
Eligibility | Inclusion Criteria: Men and women aged 10-70. The Eastern Collaborative Oncology Group (ECOG) physical status score was 0-1. Subjects with amputation can be relaxed up to 2 points. Pathological diagnosis of bone and soft tissue malignancy. Patients who have received at least one previous chemotherapy and are planning to receive new chemotherapy. All acute toxicities from previous antitumor therapy or surgery resolved to grade 0-1 (according to NCI-CTCAE, version 4.03) or to enrollment/exclusion criteria by day 1 of the first cycle (C1D1), with the exception of toxicities such as hair loss that the investigator considered to pose no safety risk to the subject). Adequate organ and bone marrow function, as defined below: Blood routine (no blood transfusion, no G-CSF, no medication correction within 7 days before screening) : Neutrophil count (ANC)=1,500/mm3(1.5×109/L); Platelet count (PLT)=100,000/mm3(100×109/L); Hemoglobin (Hb)=9g/dL(90g/L); Blood biochemical: Serum creatinine (Cr)=1.5× upper limit of normal (ULN) or creatinine clearance (Cockroft-Gault formula)=60ml/min; Total bilirubin (TBIL)=1.5×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels =2.5×ULN, and subjects with liver metastases should =5×ULN; Blood coagulation function: International normalized ratio (INR)=1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT)=1.5×ULN; With my consent and signed informed consent, I am willing and able to comply with the planned visit, study treatment, laboratory tests and other test procedures. Exclusion Criteria: Received the following treatment within 7 days before C1D1: Radiotherapy, chemotherapy, immune or molecularly targeted therapy for tumors. Some other investigational drugs. Surgery for other sites and/or radiotherapy were planned during the study period (24 hours before chemotherapy and 7 days after chemotherapy). Imaging diagnosis showed the presence of central nervous system tumor lesions. The presence of active heart disease in the 6 months before C1D1, including myocardial infarction, severe/unstable angina pectoris, etc. Poorly controlled arrhythmias with left ventricular ejection fraction <50% on echocardiography (including QTcF interval >450ms in men and >470ms in women). In the judgment of the investigator, there are concomitant diseases (such as severe diabetes, neurological or psychiatric diseases) or any other conditions that seriously endanger the safety of the subjects, may confuse the results of the study, or affect the completion of the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Henan Cancer Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anxiety and depression | Hospital Anxiety Depression Scale | 24 hours before chemotherapy | |
Primary | Anxiety and depression | Hospital Anxiety Depression Scale | 1 day of chemotherapy | |
Primary | Anxiety and depression | Hospital Anxiety Depression Scale | 24 hours after chemotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03652727 -
FX vs. ECG Guidance for PICC Insertion
|
N/A | |
Not yet recruiting |
NCT05856656 -
Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Recruiting |
NCT00797238 -
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
|
N/A | |
Not yet recruiting |
NCT05927857 -
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
|
Phase 1/Phase 2 | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT04466332 -
Comparison of Two ECG Guided PICC Insertion Techniques
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Recruiting |
NCT06208436 -
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
|
||
Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
Active, not recruiting |
NCT02304640 -
Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
|
||
Completed |
NCT02298972 -
Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
|
N/A | |
Terminated |
NCT01249001 -
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
|
Phase 2 | |
Recruiting |
NCT03089892 -
A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
|
N/A | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT04472403 -
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
|
||
Terminated |
NCT02982694 -
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
|
Phase 2 |